Group items tagged

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight. Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support. The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants. The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

This CME/CE course on Cardiovascular Health in Postmenopausal Women explores data on cardiovascular disease in this demographic, covering incidence, impact, underlying causes, and associated risk factors.

Use of cholesterol lowering drugs may significantly cut cardiovascular risks, but its long term use can raise the risk of developing cataracts by 27 percent, researchers have found.

Following the publication of a new study by the British Medical Journal (BMJ) that estimates the economic impact and prevelance of hazardous NSAID prescribing in England, the Royal Pharmaceutical Society (RPS) has underscored the pressing need for enhanced safety measures in medication management. The study, led by RPS Fellow Rachel Elliott, reveals significant health and financial costs associated with the high-risk prescribing of oral non-steroidal anti-inflammatory drugs (NSAIDs) among vulnerable populations. James Davies, Director for England at the RPS, emphasised the critical findings of the research. "Improving the safety of NSAID prescribing requires a multi-pronged approach, that educates and supports prescribers on the risk, as well as uses the skills of pharmacists in the primary care team to help identify higher risk patients and prescribing scenarios," Davies remarked. The study highlights that NSAIDs, while effective in managing pain and inflammation, are associated with serious adverse events, including gastrointestinal bleeding, renal dysfunction, and cardiovascular issues.

In partnership with the pharmaceutical company Boehringer Ingelheim, Leeds Teaching Hospitals Trust (LTHT) has recently established an innovative cardiometabolic clinic. The clinic focuses on reducing cardiovascular risk in people with diabetes who have recently been discharged from LTHT following a heart attack. It is delivered jointly by the cardiology department at Leeds General Infirmary and the diabetes services at the Trust. This is a patient-centred approach to reducing that risk, with pharmacist-delivered clinics scheduled for six to eight weeks after the heart attack. Stephen Wheatcroft, Professor of Cardiometabolic Medicine and Consultant Cardiologist at LTHT, said: "This is an exciting and innovative development, one of the first in the country. Previously, Type 2 diabetic patients presenting with heart issues would have been treated by two separate specialty teams. This is the first time there has been a specific clinic combining the cardiac and diabetes team working together. "We aim to reduce the risk for patients, with earlier multidisciplinary hospital care, to help discharged patients achieve better diabetes control, through improved medication support and optimisation, reducing the need for further treatment and future hospital stays. Overall, it will mean a better patient experience, with improved monitoring and information about treatment options, along with a reduction in waiting times for review in a specialist clinic."

Low levels of sodium are recommended for heart and high blood pressure patients, so salt intake has to cut down which further decreases chloride levels, And lower chloride levels also ups risk of cardiovascular disease.

There are multiple causes of snoring and some of them are not detrimental to health. Those can be easily cured just by changing your sleeping postures or curbing on your habit of excessive alcohol consumption. Scientists have now found out after a long-time research that obstructive sleep apnea results from a serious disorder and can up the risk of cardiovascular problem. It could indicate breaking down of cells in your veins. Link between Snoring and Heart Disease However, snoring can be a symptom of serious health issues, including cardiovascular problems. Let us take a quick look at how snoring could be a red flag for your heart health. A recent study by a group of doctors at Columbia University has identified a chain of events that define how the damage is caused in a step-wise manner. Of several problems that could cause heart attack is high blood pressure. If obstructed sleep apnea is not treated properly or in time, it could cause high blood pressure which may result in increased size of the heart, thereby being an alarming signal for strokes and heart attack.

The number of people in England identified as at risk for type 2 diabetes mellitus (T2DM) has increased by over half a million within a year, according to NHS figures. Data released by the National Diabetes Audit on June 12 showed that 3.6 million people registered with a GP were found to have non-diabetic hyperglycaemia (also known as pre-diabetes) in 2023, compared with 3.1 million people in 2022 - a notable 18 per cent increase or nearly 550,000 people. Among those under 40 years old, the figures showed an increase of almost 25 per cent from 173,166 in 2022 to 216,440 in 2023. People with non-diabetic hyperglycaemia have higher-than-normal blood sugar levels, and they are at greater risk for developing type 2 diabetes and cardiovascular diseases. Typically, this condition is detected through routine blood tests at GP surgeries.

New research is reporting that patients who experience postoperative delirium (POD) after elective heart surgery more than triple the risk of experiencing a major adverse cardiac event(MACE)like a stroke, heart attack,or cardiovascular death within just one year of discharge.

Living with diabetes can be managed by proper medication. However, you may have questions regarding the medications available to you. Here, we will take a closer look at two medications, Ozempic and Saxenda, so that you can see how these medications can impact your health. A CLOSER LOOK AT DIABETES Diabetes can be divided into two categories, type 1 diabetes (T1D) and type 2 diabetes (T2D). Type 1 diabetes is an autoimmune disorder and is commonly diagnosed in children. Individuals with T1D require lifelong insulin treatment to manage their diabetes. Type 2 diabetes is diagnosed later in life due to genetics, lifestyle, and other risk factors. Unlike T1D, there are numerous treatment options other than insulin therapy to manage type 2 diabetes. GLP-1 RECEPTOR AGONISTS A common drug class used to treat type 2 diabetes is glucagon-like peptide 1 (GLP-1) receptor agonists. GLP-1 receptor agonists work by lowering blood glucose and slowing gastric emptying. Benefits of using a GLP-1 receptor agonist include: weight loss, atherosclerotic cardiovascular disease (ASCVD) benefits, lowering A1C values, and chronic kidney disease (CKD) benefits with little risk of hypoglycemia. Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, weight loss, and injection site reactions. GLP-1 receptor agonists should not be used in patients with a personal or a family history of medullary thyroid cancer.

The company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation, and other cardiovascular procedures. The TriGuard™ and TriGUARD 3™ product pipelines are designed to help interventional cardiologists and electrophysiologists to preserve brain reserve in patients undergoing these procedures.

Lose weight quickly with the Slimming Jab at Olive Health & Travel Clinic. It also appears to improve many indicators of cardiovascular risk.

The company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation, and other cardiovascular procedures. The TriGuard™ and TriGUARD 3™ product pipelines are designed to help interventional cardiologists and electrophysiologists to preserve brain reserve in patients undergoing these procedures.

Men can now have their blood pressure checked while visiting a barbershop. The NHS is extending its blood pressure screening services to different local venues, including barbershops, mosques, and pharmacies. This initiative aims to address the increasing risk of strokes and heart attacks among men. NHS staff's life-saving actions coincide with recent data indicating that high street pharmacies administered 149,865 blood pressure checks to individuals over 40 in May 2023. This marked a notable increase from the previous year's count of 58,345 in May 2022, the NHS said. "More than 1,300 heart attacks and strokes could be prevented this year thanks to the high street checks." "The total number of blood pressure checks delivered by pharmacy teams in the year to March was more than 1 million (1,053,278)," the NHS added. Furthermore, the government has committed £645 million for a range of added pharmaceutical services. This includes a target of conducting 2.5 million extra blood pressure checks annually at community pharmacies. This effort is estimated to avert over 1,350 cardiovascular events per year - equivalent to averting 113 heart attacks and strokes each month.

A physically active lifestyle offers numerous benefits, including better cardiovascular fitness, healthy body weight, management of chronic illnesses like diabetes and arthritis, and improved bone health and muscular fitness. However, like the cliché statement that every action attracts an adverse reaction, physical activity has its fair share of risks, including injuries. Some common body injuries while engaging in various levels of physical activity or active sports include wrist, knee, and ankle injuries. The most common injuries are bruises, strains, and sprains, and this article focuses on the latter. A sprain is an acute soft tissue injury when ligaments get torn or stretched excessively. Ligaments are tough fibrous tissues made of collagen that connect the bones and form the different joints found in human bodies. Therefore, sprains are joint injuries, with ankles taking the giant share of most sprain injuries. It's also important to note that sprains are often confused with strains. However, they're distinctly different because the former are injuries to the ligaments in a joint, while the latter are injuries to the muscles.

Esperion Therapeutics' non-statin therapy "bempedoic acid" has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company. As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said GlobalData. According to GlobalData's Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025. Neha Myneni, Pharma Analyst at GlobalData, comments: "Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses. However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space." Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins, niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).

In the latest research to tout the cardiovascular benefits of an already beloved food, Swedish scientists report that eating chocolate seems to lower a woman's risk of stroke.

The National Health Service (NHS) has said that the roll-out of blood-thinning drugs has helped save thousands of lives. In January 2022, the NHS launched a drive to rapidly expand the use of life-saving direct oral anticoagulants (DOACs) in people who are at increased risk of strokes. Since then, more than 24 million prescriptions have been given to such patients and around 460,000 more people have started taking the drugs. This prevented an estimated 17,000 strokes and 4,000 deaths in the last 18 months, as revealed by the new NHS data. Amanda Pritchard, the NHS chief executive, hailed the "lifesaving NHS rollout" at the King's Fund annual conference. It is part of a major NHS drive on "prevention" - to catch more killer conditions earlier and save more lives.

Low vitamin D levels are common and are linked to a number of risk factors for cardiovascular disease, new evidence suggests.